Management of Gastrointestinal Bleeding Under Direct Oral Anticoagulants

Recruiting Observational Study
Gastrointestinal Bleeding
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
250 (estimated)
Sponsor
University Hospital, Strasbourg, France · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Gastrointestinal bleeding (GIB) is a common emergency in hepatology and gastroenterology, with an overall mortality rate ranging from 5% to 10% depending on the study. GIB is classified into two categories: upper GIB (80% of cases) and lower GIB (20% of cases). There are many risk factors for GIB, including anticoagulants. In cases of GD under anticoagulants, there are specific management recommen…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult patient (≥ 18 years) * Male or female * Patient admitted to the emergency department for gastrointestinal bleeding (hematemesis, melena, rectal bleeding, or hematochezia) * Taking a direct oral anticoagulant (dabigatran, apixaban, or rivaroxaban) Exclusion Criteria: * …
Contacts

Valérie WILME, MD

33 3 88 11 67 68

valerie.wilme@chru-strasbourg.fr

CONTACT